Veraxa Biotech to merge with SPAC Voyager in $1.64 billion deal
23/04/2025 06:19
April 23 (Reuters) - Switzerland's Xlife Sciences AG XLS.S said on Wednesday its portfolio company, VERAXA Biotech AG, will merge with Voyager Acquisition VACH.O in a deal that will value the combined company at $1.64 billion. (Reporting by Bipasha Dey in Bengaluru; Editing by Janane Venkatraman) ((Bipasha.Dey@thomsonreuters.com;))
Recent news on Xlife Sciences AG
See all newsSwiss stocks - Factors to watch on July 17
Brief: Xlife Sciences AG Says Transaction With Veraxa, Offers Potential For A Significant Partial Exit Of Company's Investment
Veraxa Biotech to merge with SPAC Voyager in $1.64 billion deal (updated)
Veraxa Biotech to merge with SPAC Voyager in $1.64 billion deal
Brief: Xlife Sciences AG Says Veraxa Biotech AG To Merge With Voyager Acquisition Corp.